Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Uehara K, Maeda A, Sakamoto E, Hiramatsu K, Takeuchi E, Sakaguchi K, Tojima Y, Takahashi Y, Ebata T, Nagino M. Uehara K, et al. Among authors: tojima y. Ann Surg Oncol. 2013 Feb;20(2):475-81. doi: 10.1245/s10434-012-2665-z. Epub 2012 Sep 11. Ann Surg Oncol. 2013. PMID: 22965575 Clinical Trial.
Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Nagino M, Kodera Y. Hattori N, et al. Among authors: tojima y. Int J Clin Oncol. 2020 Jan;25(1):118-125. doi: 10.1007/s10147-019-01546-3. Epub 2019 Sep 21. Int J Clin Oncol. 2020. PMID: 31542847 Free PMC article. Clinical Trial.
Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, Nakayama H, Yamashita K, Sakamoto E, Tojima Y, Kawai S, Kodera Y, Nagino M; Nagoya Surgical Oncology Group and the Chubu Clinical Oncology Group. Kamiya T, et al. Among authors: tojima y. Eur J Surg Oncol. 2016 Jun;42(6):829-35. doi: 10.1016/j.ejso.2016.02.014. Epub 2016 Feb 27. Eur J Surg Oncol. 2016. PMID: 26968228 Clinical Trial.
NAK is an IkappaB kinase-activating kinase.
Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, Kaneko Y, Nimura Y, Motoyama N, Ikeda K, Karin M, Nakanishi M. Tojima Y, et al. Nature. 2000 Apr 13;404(6779):778-82. doi: 10.1038/35008109. Nature. 2000. PMID: 10783893
32 results